Back

Cardioprotective anti inflammatory effects of empaglifozin in doxorubicin induced cardiotoxicity: the role of leukotriene B4 and interleukin 1

3 September 2019 (12:40 - 13:30)
Organised by:
Congress Presentation Part of: Cardiovascular pharmacotherapy Cardiotoxicity of Drugs ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Nicola Maurea

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

6 More presentations in this session

Presentation thumbnail
Research Network in Africa (RNA): quality assessment of antihypertensive generic drugs in 10 African countries
Doctor D. Macquart de Terline (Paris, FR)
Abstract
Presentation thumbnail
Clinical pharmacology of AZD9977, a novel, selective mineralocorticoid receptor (MR) modulator without K+-sparing properties
Doctor A. Whittaker (Gothenburg, SE)
Abstract
Presentation thumbnail
Impact on the prognosis of treatment administrated in the daily clinical practice to patients with myocardial infarction with non-obstructive coronary arteries.
Doctor J. Lopez-Pais (Santiago de Compostela, ES)
Abstract Slides
Presentation thumbnail
Trends in indications and outcome in thrombolytic therapy: a retrospective single center study
Doctor M. Engelen (Leuven, BE)
Abstract Slides
Presentation thumbnail
Risk of qtc interval prolongation among cancer patients treated with tyrosine kinase inhibitors
Slides

Access the full session

Session thumbnail
Cardiovascular pharmacotherapy

The Event

Event poster

ESC Congress 2019

3 September 2019 12:40 CET
You may be interested in
thumbnail
Webinar
Multidisciplinary strategies for monitoring and managing cardiovascular toxicity in patients with cancer
thumbnail
Congress Session
Recent perspectives in cardio-oncology
thumbnail
Congress Session
Cardio-oncology: when therapy leads to failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources